https://www.live-feeds.com/feed/moderna-and-merck-shares-soar-on-mrna-cancer-vaccineContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-and-merck-shares-soar-on-mrna-cancer-vaccinehttps://www.live-feeds.com/feed/moderna-and-merck-shares-soar-on-mrna-cancer-vaccine#u45716Fri, 21 Aug 2026 03:15:27 +0000Moderna and Merck developed an mRNA cancer vaccine that prevents melanoma from returning, according to results from a large late-stage trial. The success triggered a surge in share prices for both companies, with Moderna stock jumping between 90% and 160%. This price spike caused an estimated $5 billion loss for investors betting against the stock. The breakthrough suggests a potential new wave of mRNA-based treatments for various types of cancer beyond skin cancer.Why it mattersmRNA technology gained global prominence during the COVID-19 pandemic. Applying this platform to oncology allows for